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Associations of obesity with triglycerides and
C-reactive protein are attenuated in adults with
high red blood cell eicosapentaenoic and
docosahexaenoic acids
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CB Stephensen4, KL Stanhope5, PJ Havel5 and B Boyer3
1Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2Biostatistics and Biomathematics Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA,
USA; 3The Center for Alaska Native Health Research, Institute of Arctic Biology, University of Alaska-Fairbanks, Fairbanks, AK, USA;
4United States Department of Agriculture/Agricultural Research Service, Western Human Nutrition Research Center, University of
California-Davis, Davis, CA, USA and 5Department of Molecular Biosciences, School of Veterinary Medicine, and Department of
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Background: N-3 fatty acids are associated with favorable, and obesity with unfavorable, concentrations of chronic disease risk
biomarkers.
Objective: We examined whether high eicosapentaenoic (EPA) and docosahexaenoic (DHA) acid intakes, measured
as percentages of total red blood cell (RBC) fatty acids, modify associations of obesity with chronic disease risk biomarkers.
Methods: In a cross-sectional study of 330 Yup’ik Eskimos, generalized additive models (GAM) and linear and quadratic
regression models were used to examine associations of BMI with biomarkers across RBC EPA and DHA categories.
Results:Median (5th–95th percentile) RBC EPA and DHA were 2.6% (0.5–5.9%) and 7.3% (3.3–8.9%), respectively. In regression
models, associations of BMI with triglycerides, glucose, insulin, C-reactive protein (CRP) and leptin differed significantly by RBC EPA
and DHA. The GAM confirmed regression results for triglycerides and CRP: at low RBC EPA and RBC DHA, the predicted increases in
triglycerides and CRP concentrations associated with a BMI increase from 25 to 35 were 99.5±45.3mg/dl (106%) and
137.8±71.0mg/dl (156%), respectively, for triglycerides and 1.2±0.7mg/l (61%) and 0.8±1.0mg/l (35%), respectively, for
CRP. At high RBC EPA and RBC DHA, these predicted increases were 13.9±8.1mg/dl (23%) and 12.0±12.3mg/dl (18%),
respectively, for triglycerides and 0.5±0.5mg/l (50%) and 0.5±0.6mg/l (34%), respectively, for CRP.
Conclusions: In this population, high RBC EPA and DHA were associated with attenuated dyslipidemia and low-grade systemic
inflammation among overweight and obese persons. This may help inform recommendations for n-3 fatty acid intakes in the
reduction of obesity-related disease risk.
European Journal of Clinical Nutrition (2011) 65, 808–817; doi:10.1038/ejcn.2011.39; published online 23 March 2011
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Introduction
The very long-chain n-3 polyunsaturated fatty acids eicosa-
pentaenoic acid (EPA; 20:5(n-3)) and docosahexaenoic acid
(DHA; 22:6(n-3)), found primarily in fish and marine
mammals, are associated with reduced risks of cardiovascular
disease (CVD) (Kris-Etherton et al., 2002) and possibly
diabetes (Nettleton and Katz, 2005). EPA and DHA have
important biological functions including increased mem-
brane fluidity, which affects nutrient transport and signal
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transduction (Alexander, 1998), eicosanoid metabolism
(Fritsche, 2006) and gene expression and transcription
(Sampath and Ntambi, 2005). In particular, high EPA and
DHA intakes are associated with reduced concentrations of
triglycerides (Bonaa et al., 1992; Dewailly et al., 2001a, b,
2002; Okuda et al., 2005; Ferrucci et al., 2006; Block et al.,
2008; He et al., 2008; Motoyama et al., 2009), C-reactive
protein (CRP) (Klein-Platat et al., 2005; Niu et al., 2006;
Farzaneh-Far et al., 2008) and pro-inflammatory cytokines,
and increased concentrations of high-density lipoprotein
(HDL) (Dewailly et al., 2001a, b, 2002; Okuda et al., 2005;
Block et al., 2008; He et al., 2008; Motoyama et al., 2009) and
anti-inflammatory cytokines (Fritsche, 2006). Most of these
biomarkers are also associated, although in the opposite
direction, with obesity (Pi-Sunyer, 2002), which raises the
question of whether the associations of obesity with chronic
disease risk biomarkers could be modified by high EPA and
DHA intakes.
To address this question, we analyzed data from Yup’ik
Eskimos living in the Yukon Kuskokwim Delta region in
Southwest Alaska, a population with mean (±s.d.) EPA and
DHA intakes 420 times the current mean intakes of the
general US population (4.1±0.5g/day versus 0.05 g/day
in men and 2.8±0.3g/day versus 0.09g/day in women)
(Bersamin et al., 2008; Johnson et al., 2009) and obesity
prevalence similar to that of the overall US population
(Mohatt et al., 2007). Results of this study may provide
evidence useful for developing recommendations for EPA and
DHA intakes in the reduction of obesity-related disease risk.
Materials and methods
Participant recruitment and procedures
Data are from the Center for Alaska Native Health Research
study, a cross-sectional community-based participatory study
of obesity and disease risk in Yup’ik Eskimos. Study protocols
were approved by the Institutional Review Boards of the
University of Alaska, the National and Alaska Area Indian
Health Service and the Yukon Kuskokwim Health Corpora-
tion Human Studies Committee.
Participant recruitment and procedures are described
elsewhere (Boyer et al., 2005; Mohatt et al., 2007). In brief,
between 2003 and 2006, 1003 participants aged X14 years
and residing in 10 Southwest Alaskan communities were
enrolled. Extensive socio-demographical and health-related
data were collected through in-person interviews and self-
administered questionnaires. Diet was assessed using a
24-h dietary recall and a 3-day food record. Height,
weight, percent body fat (through bioelectrical impedance)
and blood pressure were measured. Physical activity was
measured using pedometers (counts/h). Blood samples
collected in the field were separated into serum, plasma
and packed RBC, frozen and stored locally at 20 1C for up to
6 days and transferred to a central location and stored
at 80 1C.
Study sample
Blood samples in this study were from a subset of 497
participants selected from 7 out of the 10 participating
communities. From four communities, we selected a random
sample of 84 participants balanced across age strata (14–19,
20–49 and X50 years). The remaining three communities
had o84 participants, and thus all participants were
included. We excluded 92 participants aged p18 years, 28
with CRP41mg/dl (acute inflammation), 20 with missing
data on biochemical measurements, 10 with BMIo20 and 17
with BMI440, leaving 330 for the present analyses.
Biochemical measurements
Disease risk measures examined in this study included:
systolic blood pressure (SBP); diastolic blood pressure (DBP);
triglycerides; low-density lipoprotein (LDL); HDL; total
cholesterol; apolipoprotein A1 (apoA1); glucose; insulin;
homeostasis model assessment of insulin resistance (HOMA-
IR) index; insulin-like growth factor-I (IGF1); insulin-like
growth factor binding protein-3 (IGFBP3); CRP; interleukin-6
(IL6); soluble tumor necrosis factor receptor-2 (sTNFR2);
leptin; and adiponectin. Triglycerides, HDL, total cholesterol
and apoA1 were measured with the Poly-Chem System
Chemistry Analyzer (Polymedco Inc., Cortlandt Manor, NY,
USA). Intra- and inter-assay coefficients of variation (CV)
were, respectively: 3.2 and 4.1% for triglycerides; 3.6 and
3.9% for HDL; 1.8 and 6.2% for total cholesterol; and 2.7 and
4.5% for apoA1. LDL was calculated as: total cholesterol
HDL(triglycerides/5). Leptin, total adiponectin and fasting
insulin were assayed using human-specific radioimmunoas-
say kits (Linco Research Inc., St Charles, MO, USA). Intra-
and inter-assay CV were, respectively: 6.6 and 12.0% for
leptin; 5.1 and 9.1% for adiponectin; and 5.8 and 10.2% for
insulin. Fasting blood glucose was measured with a Choles-
tech LDX analyzer (Hayward, CA, USA). Insulin resistance
was assessed using the HOMA-IR index: (fasting insulin
(mU/ml) fasting glucose (mg/dl))/405 (Matthews et al.,
1985). CRP was measured with an Immulite Analyzer and
high sensitivity CRP reagents (Diagnostic Products Corpora-
tion, Los Angeles, CA, USA). Manufacturer’s intra- and inter-
assay CV were 2.8 and 3.3%, respectively. IGF1, IGFBP3, IL6
and sTNFR2 were assayed using ELISA kits (Biosource,
Carlsbad, CA, USA and Diagnostic Systems Laboratories
Inc., Webster, TX, USA). Intra- and inter-assay CV were,
respectively: 6.5 and 5.4% for IGF1; 8.8 and 10.0% for
IGFBP3; 6.4 and 7.8% for IL6; and 4.2 and 3.3% for sTNFR2.
RBC fatty-acid measurements
RBC fatty acids were analyzed as previously described
(O’Brien et al., 2009). Briefly, fatty acids were extracted from
washed RBC with 2-propanol and chloroform (Rose and
Oklander, 1965). Fatty acids were converted to fatty acid
methyl esters (FAME) by direct transesterification (Lepage
and Roy, 1986). FAME were recovered in hexane, dried under
N-3 fatty acids and obesity-related disease risk
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nitrogen (40 1C) and re-dissolved in hexane for gas chromato-
graphy analysis. The FAME of individual fatty acids
were separated on a gas chromatograph (Model 5890B,
Hewlett-Packard (HP), Agilent, Santa Clara, CA, USA)
equipped with a flame ionization detector, automatic sampler
(HP 7673), electronic pressure programming (HP) and
Chemstation software (HP). Quantitative precision and
identification were evaluated using model mixtures of known
FAME and an established control pool. The inter-assay CV was
2.7% for EPA and 2.0% for DHA. RBC EPA and DHA
composition is reported as a weight percentage of total RBC
fatty acids.
Statistical analyses
Triglycerides, HOMA-IR index, CRP, IL6, sTNFR2 and leptin
concentrations were log-transformed. IL6 values (n¼ 90)
below the limit of detection (0.02pg/ml) were replaced with
0.02/
ﬃﬃﬃ
2
p
(Hornung and Reed, 1990). Outliers for triglycerides
(n¼ 1), glucose (n¼1), insulin (n¼1), adiponectin (n¼ 1),
apoA1 (n¼2) and sTNFR2 (n¼3) were excluded because they
were 44 s.d. above the mean and were physiologically
unreasonable.
Participants’ demographic and health-related characteris-
tics are given for the entire sample and stratified by BMI
(kg/m2):o25 (normal-weight), 25–30 (overweight) andX30
(obese). Values are presented as means (±s.d.) or propor-
tions, which were compared across BMI categories using
ANOVA F-test and w2 test, respectively.
Age- and sex-adjusted means of biomarkers stratified by
BMI were computed using least square means. Adjusted
means are presented with SE and log-transformed means are
back-transformed for ease of interpretation and given with
95% CI. Tests for significant linear trends across BMI
categories were based on age- and sex-controlled linear
regression models.
We used three approaches to describe the associations of
BMI with disease biomarkers at different RBC EPA and DHA
levels. First, we used linear regression to test whether the
BMI-biomarker associations differed significantly across the
following RBC EPA and DHA categories: o25th percentile,
25th–75th percentiles and 475th percentile (o1.5, 1.5–3.9
and 43.9% for EPA; o5.8, 5.8–8.2 and 48.2% for DHA).
Because we could not assume linear associations of BMI with
disease biomarkers, we examined both linear and quadratic
models in that the F-test for the interaction of BMI with RBC
EPA and DHA categories was used to determine statistical
significance. We report the linear models for all biomarkers
and the quadratic models only when statistically significant.
Second, we used non-parametric generalized additive models
(GAM) (Wood, 2006) that included a two-dimensional thin-
plate regression spline over BMI and RBC EPA and DHA to
graphically display the BMI-biomarker associations across
RBC EPA and DHA. GAM enable the fitted associations to
take their natural shapes by relaxing assumptions about
the form of the functional associations. To illustrate typical
BMI-biomarker associations for the three RBC EPA and DHA
categories, we present the estimated two-dimensional
covariate-adjusted GAM at the 10th, 50th and 90th percen-
tiles of RBC EPA (1, 3 and 5%) and DHA (4, 7 and 9%). Third,
on the basis of GAM, we predicted mean concentrations
(±s.e.) of biomarkers at the 10th and 90th percentiles of RBC
EPA and DHA for BMI 25, 30 and 35 using simple case
resampling over 1000 bootstrap replicates. All models were
adjusted for age (continuous), sex and current smoking
(yes/no). Models for IGF1 were additionally adjusted for
IGFBP3. We also considered whether control for RBC n-6
fatty acids, dietary macronutrient intake and physical
activity would modify interactions between BMI and RBC
EPA and DHA, because these can affect disease biomarkers.
However, control for these variables did not affect results and
these are therefore not included in final models. Alcohol
consumption is prohibited in the participating Yup’ik
communities and was therefore not considered as a potential
covariate.
We report results for EPA and DHA separately for two
reasons. First, DHA intake is very high in this population and
although RBC EPA increases linearly in response to dietary
intake, RBC DHA plateaus at E9% of total fatty acids
(O’Brien et al., 2009), suggesting that RBC DHA does not
reflect variability at high intake (Arterburn et al., 2006; Cao
et al., 2006). Second, previous studies reported differential
associations of EPA and DHA with disease biomarkers (Mori
et al., 2000; Leigh-Firbank et al., 2002; Egert et al., 2009). We
also present results for the n-3 index (RBC EPAþDHA)
(Harris, 2009) as Supplementary Material.
Statistical analyses were carried out using Stata/SE 11.0
(StataCorp LP, College Station, TX, USA) and the R package
mgcv version 1.4-0 (R-Project, 2009).
Results
Overall, the median age was 45.5 years, 57% were
women and 71% were overweight or obese. RBC EPA and
DHA ranged from 0.2 to 9.6% and 1.6 to 10.3%, respectively,
with medians (5th–95th percentile) of 2.6 (0.5–5.9%) and
7.3% (3.3–8.9%). Women were more likely to be overweight
and obese than men and smokers were less likely to be obese
than non-smokers. There was a significant trend for
increased BMI with increasing age. Dietary energy, total fat,
carbohydrate, protein, EPA and DHA intakes, the
means of RBC EPA and DHA and n-3 index and the
proportions of persons in each RBC EPA and DHA and n-3
index category did not differ significantly across BMI groups
(Table 1).
BMI was positively associated with higher SBP, DBP,
triglycerides, glucose, insulin, HOMA-IR index, CRP and
leptin, and negatively associated with HDL, apoA1
and adiponectin. Mean LDL, total cholesterol, IGF1, IL6
and sTNFR2 concentrations did not differ significantly by
BMI (Table 2).
N-3 fatty acids and obesity-related disease risk
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Associations of BMI with disease biomarkers across RBC EPA and
DHA
On the basis of either the linear or quadratic models (models
1 or 2 in Table 3, respectively), the associations of BMI with
triglycerides, CRP, glucose and insulin differed significantly
by both RBC EPA and DHA; associations with leptin differed
only by RBC DHA. To best display these associations, Figure 1
and Supplementary Figure 1 show the GAM for the BMI-
biomarker associations plotted at the 10th, 50th and 90th
percentiles of RBC EPA and DHA. We also inspected the GAM
for the other biomarkers and found that they were consistent
with the lack of statistical significance in linear models. The
linear but not quadratic models best approximated the GAM
shown in Figure 1 and Supplementary Figure 1, and therefore
only the linear models are described below. Similar results
were obtained, when using the n-3 index in the regression
models (Supplementary Table) and GAMs (Supplementary
Figure 2).
Triglycerides. In linear regression models, the positive
associations of BMI with triglycerides were attenuated with
increasing RBC EPA and DHA concentrations (Table 3). The
GAM showed strong positive associations of BMI with
triglycerides at low RBC EPA and DHA concentrations, which
became weaker at moderate concentrations and flat at high
concentrations (Figure 1a). At low RBC EPA and DHA, the
predicted increases in triglyceride concentrations associated
with a BMI increase from 25 to 35 were 99.5±45.3mg/dl
Table 1 Demographic, dietary and health-related characteristics of all study participants and stratified by BMIa
All b BMI (kg/m2)c P-trend d
o25 25–30 X30
n 330 96 123 111
Sex
Women 187 (57) 44 (23) 64 (34) 79 (42) o0.01
Men 143 (43) 52 (36) 59 (41) 32 (22)
Age (years) 44.8±15.4 41.9±15.4 44.8±15.5 47.3±15.0 0.04
18–29 65 (20) 25 (38) 26 (40) 14 (21) 0.11
30–54 169 (51) 49 (29) 58 (34) 62 (37)
X55 96 (29) 22 (23) 39 (41) 35 (36)
BMI (kg/m2) 28.1±4.8 22.7±1.2 27.3±1.4 33.6±2.8 o0.001
Body fat (%) 30.9±9.5 22.1±6.3 29.8±6.2 39.7±6.7 o0.001
Current smokers 92 (28) 40 (43) 25 (27) 27 (29) o0.01
Energy intake (kcal/day) 1953±878 2013±903 2000±948 1839±752 0.32
Total fat
(g/day) 87±55 89±58 89±61 83±45 0.65
(% energy) 38±11 37±12 38±10 39±11 0.63
Carbohydrate
(g/day) 208±114 223±116 207±120 196±103 0.27
(% energy) 44±14 46±13 43±14 43±14 0.27
Protein
(g/day) 87±47 83±35 95±61 82±35 0.09
(% energy) 19±7 18±6 20±8 19±8 0.13
Dietary EPA (g/day) 1.6±2.2 1.3±1.9 1.9±2.7 1.6±2.0 0.16
Dietary DHA, (g/day) 1.9±2.7 1.6±2.2 2.2±3.2 1.8±2.2 0.24
RBC EPA (% of total fatty acids)e 2.8±1.8 2.5±1.5 2.9±2.0 3.0±1.8 0.09
o1.5 87 (26) 26 (30) 33 (38) 28 (32) 0.17
1.5–3.9 161 (49) 54 (33) 59 (37) 48 (30)
43.9 82 (25) 16 (19) 31 (38) 35 (43)
RBC DHA (% of total fatty acids)e 6.8±1.8 6.6±1.7 6.8±1.8 7.0±1.8 0.17
o5.8 84 (25) 29 (34) 30 (36) 25 (30) 0.25
5.8–8.2 168 (51) 51 (30) 64 (38) 53 (32)
48.2 78 (24) 16 (20) 29 (37) 33 (42)
N-3 index (% of total fatty acids)e,f 9.6±3.4 9.0±3.0 9.8±3.5 10.0±3.4 0.11
o7.0 83 (25) 28 (34) 30 (36) 25 (30) 0.25
7.0–12.1 164 (50) 51 (31) 62 (38) 51 (31)
412.1 83 (25) 17 (20) 31 (37) 35 (42)
Abbreviations: BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; RBC, red blood cell.
aValues are means±s.d. or n (%). Percentages may not sum to 100 because of rounding.
bPercentages are column percents.
cPercentages are row percents.
dBased on tests for trend across BMI using F-tests from ANOVA for continuous variables and w2 tests for categorical variables.
eCategorized as o25th percentile, 25th to 75th percentiles and 475th percentile.
fRBC EPA þ DHA.
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(106%) and 137.8±71.0mg/dl (156%), respectively. At high
RBC EPA and DHA, these predicted increases were 13.9±8.1
mg/dl (23%) and 12.0±12.3mg/dl (18%), respectively.
C-reactive protein. In linear regression models, the positive
association of BMI with CRP was modestly, but not
significantly, attenuated in the moderate and high RBC
EPA categories and the high RBC DHA category (Table 3). The
GAM showed clear differential associations of BMI with CRP
by RBC EPA and DHA at BMI428; strong positive associa-
tions of BMI with CRP among persons with low RBC EPA and
DHA were weak at moderate concentrations and flat at high
concentrations (Figure 1b). At low RBC EPA and DHA, the
predicted increases in CRP concentrations associated with a
BMI increase from 30 to 35 were 0.8±0.7mg/l (32%) and
1.0±0.8mg/l (45%), respectively. At high RBC EPA and DHA,
these predicted increases were 0.1±0.6mg/l (6%) and
0.5±0.6mg/l (32%), respectively. Similarly, an increase
in BMI from 25 to 35 at low versus high RBC EPA and DHA
was associated with similar, although less significant,
differences in the predicted increases in CRP concentrations.
These were 1.2±0.7mg/l (61%) and 0.8±1.0mg/l (35%) at
low RBC EPA and DHA, respectively, and 0.5±0.5mg/l (50%)
and 0.5±0.6mg/l (34%) at high RBC EPA and DHA,
respectively.
Glucose and insulin. In linear regression models, there were
significant positive associations of BMI with glucose in the
highest RBC EPA and DHA categories, which were signifi-
cantly and similarly attenuated in the moderate and low
RBC EPA and DHA categories (Table 3). For insulin, there
were significant positive associations with BMI in the
lowest category of RBC EPA and DHA, which were slightly,
but not significantly, attenuated in the moderate and high
RBC EPA and DHA categories (Table 3). The GAM for glucose
and insulin (Supplementary Figure 1) were complex but
overall showed no differential associations with BMI by RBC
EPA and DHA.
Leptin. The positive association of BMI with leptin was
significantly weaker in the high compared with the moder-
ate and low categories of RBC DHA (Table 3). However, GAM
showed no differential association by RBC DHA (Supple-
mentary Figure 1).
Discussion
In this population-based sample of Yup’ik Eskimos, the
strong positive associations of obesity with triglycerides and
CRP concentrations were substantially attenuated in adults
Table 2 Age- and sex-adjusted means of biomarkers of chronic disease risk for all study participants and stratified by BMIa
All BMI (kg/m2) P-trend b
o25 25–30 X30
n 330 96 123 111
SBP (mmHg) 124.1±0.8 121.6±1.5 123.4±1.3 127.1±1.4 0.009
DBP (mmHg) 72.7±0.5 68.8±0.9 71.7±0.8 77.0±0.9 o0.001
Triglycerides (mg/dl)c,d 80.5 (76.9–84.3) 66.0 (60.9–71.6) 77.1 (71.9–82.7) 99.9 (92.7–107.7) o0.001
Total cholesterol (mg/dl)e 223.0±2.3 223.5±4.3 228.5±3.7 216.6±4.0 0.23
LDL cholesterol(mg/dl)e 142.2±2.0 138.7±3.8 147.0±3.3 139.9±3.6 0.87
HDL cholesterol (mg/dl)e 62.7±0.9 71.0±1.5 64.7±1.3 53.4±1.4 o0.001
ApoA1 (g/l) 1.74±0.01 1.83±0.02 1.77±0.02 1.64±0.02 o0.001
Glucose (mg/dl)f 95.1±0.6 91.4±1.0 94.5±0.9 99.0±1.0 o0.001
Insulin (mU/ml)g 15.0±0.4 12.0±0.6 13.9±0.5 18.7±0.6 o0.001
HOMA-IRc 3.2 (3.1–3.4) 2.5 (2.3–2.7) 3.1 (2.8–3.3) 4.2 (3.9–4.6) o0.001
IGF1 (mg/l) 266.6±4.7 267.1±8.8 265.6±7.7 267.4±8.2 0.98
IGFBP3 (mg/l) 4391±51 4240±93 4227±81 4699±86 o0.001
CRP (mg/l)c 0.9 (0.8–1.1) 0.7 (0.5–0.9) 0.9 (0.7–1.0) 1.3 (1.1–1.6) o0.001
IL6 (ng/l)c 0.08 (0.07–0.09) 0.07 (0.06–0.10) 0.07 (0.06–0.09) 0.10 (0.08–0.12) 0.17
sTNFR2 (ng/l)c 1995 (1869–2129) 1963 (1734–2223) 1974 (1773–2198) 2045 (1824–2292) 0.64
Leptin (mg/l)c 8.0 (7.4–8.6) 4.1 (3.7–4.5) 8.0 (7.3–8.7) 13.9 (12.7–15.3) o0.001
Adiponectin (mg/l) 8.8±0.2 11.3±0.4 9.0±0.3 6.4±0.4 o0.001
Abbreviations: ApoA1, apolipoprotein A1; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment of insulin resistance; IGF1, insulin-like growth factor-I; IGFBP3, insulin-like growth factor binding protein-3; IL6, interleukin-6; LDL, low-density
lipoprotein; SBP, systolic blood pressure; sTNFR2, soluble tumor necrosis factor receptor-2.
aValues are age- and sex-adjusted means±s.e. or geometric means (95% CI) for log-transformed variables.
bP values for trend across BMI categories based on linear regression models adjusted for age and sex.
cLog-transformed values were used in the least square means analysis; adjusted means and 95% CIs were back-transformed.
dTo convert triglycerides from mg/dl to mmol/l, multiply by 0.0113.
eTo convert cholesterol (total, HDL and LDL) from mg/dl to mmol/l, multiply by 0.0259.
fTo convert glucose from mg/dl to mmol/l, multiply by 0.0555.
gTo convert insulin from mU/ml to pmol/l, multiply by 6.945.
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with high RBC EPA and DHA. There were suggestive findings
for glucose, insulin and leptin in linear regression models,
but GAM provided little support for differential associations
of BMI with these biomarkers at different RBC EPA and DHA
levels. We judge the GAM to better represent associations of
obesity with disease biomarkers (discussed below) and
therefore consider the limited findings for glucose, insulin
and leptin to be uninformative. There were no differential
associations of BMI with all other biomarkers by RBC EPA
and DHA levels.
Most studies on the associations of EPA and DHA with
chronic disease biomarkers were conducted in populations
with relatively low and narrow range of EPA and DHA
intakes and none of these studies examined the interactions
of EPA and DHA with obesity. However, a number of
published studies indirectly support our findings. First,
obesity is strongly associated with elevated triglycerides
(Lamon-Fava et al., 1996). Second, most observational
studies (Bonaa et al., 1992; Ferrucci et al., 2006; Block et al.,
2008; He et al., 2008; Motoyama et al., 2009), including those
on populations with chronic, high EPA and DHA intakes
(Dewailly et al., 2001b, 2002), and supplementation studies
(Mori et al., 2000; Leigh-Firbank et al., 2002; Woodman et al.,
2002; Maki et al., 2005; Schwellenbach et al., 2006; Kelley
et al., 2007; Damsgaard et al., 2008) reported decreased
triglycerides concentrations with increasing EPA and DHA
intakes.
Similarly, obesity is strongly and positively associated with
CRP (Visser et al., 1999). Furthermore, most observational
studies reported inverse associations of EPA and DHA intakes
with CRP (Fernandez-Real et al., 2003; Pischon et al., 2003;
Lopez-Garcia et al., 2004; Klein-Platat et al., 2005; Niu et al.,
2006). The single study that addressed whether these
associations differed by BMI found a stronger association of
EPA with CRP among overweight versus normal-weight
adolescents (Klein-Platat et al., 2005), a finding consistent
with ours. Most EPA and DHA supplementation studies
found no effect on CRP (Madsen et al., 2003; Fujioka et al.,
2006; Damsgaard et al., 2008; Yusof et al., 2008). These
studies did not examine the interaction of obesity with EPA
and DHA. The effect may be specific to a BMI subgroup and
therefore could not be detected in the overall sample.
Moreover, associations of EPA and DHA with CRP may be
nonlinear, as previously shown (Makhoul et al., 2010), and
therefore could not be detected using conventional linear
regression models.
Our findings may have important clinical relevance for the
prevention of some obesity-related diseases. Obesity pre-
valence in the US (Ogden et al., 2006) and worldwide
(James et al., 2001) has been increasing over the past decades,
with subsequent increases in rates of diabetes and other
obesity-associated diseases (Pi-Sunyer, 2002). It is likely that
these associations are partly mediated by the positive
associations of obesity with triglycerides and CRP, two
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Figure 1 GAM of the associations of BMI with triglycerides (a) and CRP (b) by EPA and DHA, as percentages of total fatty acids in RBC. The
GAM include a bivariate smooth surface over EPA or DHA and BMI (all continuous). The estimated GAM was evaluated at mean values of age,
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biomarkers that strongly and independently predict risks of
CVD (Pai et al., 2004; Nordestgaard et al., 2007) and possibly
diabetes (Pradhan et al., 2001; Tirosh et al., 2008; Hu et al.,
2009). Chronic, high EPA and DHA intakes, similar to those
of Yup’ik Eskimos, could at least partly ameliorate the
obesity-associated disease risks.
Indeed, observations in Yup’ik Eskimos suggest that EPA
and DHA intakes may lower their risk for diabetes. Yup’ik
Eskimos have levels of obesity similar to those observed in
the general US population and yet their prevalence of
type 2 diabetes is significantly lower (3.3% (Mohatt et al.,
2007) versus 7.7% in NHANES 2005–2006 (Cowie et al.,
2009)). We recognize that genetic, lifestyle and dietary
factors may account for this difference; yet it is consistent
with our findings that chronic, high EPA and DHA
consumption in Yup’ik Eskimos may protect overweight
and obese persons against obesity-associated dyslipidemia
and low-grade systemic inflammation, and as a result may
partially explain the low prevalence of diabetes in this
population.
This study has several strengths. First, our study popula-
tion was uniquely suitable for examining associations among
BMI, disease biomarkers and RBC EPA and DHA: Yup’ik
Eskimos have a broad range of EPA and DHA intakes
(Bersamin et al., 2008) and also a broad BMI distribution
(Mohatt et al., 2007). Second, we used RBC EPA and DHA
concentrations, in preference to diet assessment, because
they provide unbiased dietary intake measures and they
better reflect biologically relevant exposure. Third, our
analytical approach of using both GAM and linear regression
was unique: linear models provide straightforward inference
about the dependence of BMI-biomarker associations on EPA
and DHA, whereas GAM allow for a more data-driven
quantification of these associations based on a more flexible
set of model assumptions (Wood, 2006).
This study also has limitations. First, although RBC EPA
and DHA were previously found to be significantly
associated with HDL, LDL and total cholesterol (Makhoul
et al., 2010), we did not detect statistically significant
differences in the associations of BMI with these biomarkers
at different RBC EPA and DHA levels probably due to limited
sample size in the RBC EPA and DHA categories. Second, this
study was cross-sectional and associations observed may not
be causal. Third, although we adjusted for several confoun-
ders, we are aware that unmeasured factors could affect RBC
fatty-acids composition (such as fatty-acid desaturase gene
polymorphisms) (Simopoulos, 2010), weight and disease
biomarkers. Finally, our findings require replication in other
populations.
In conclusion, high EPA and DHA intakes may attenuate
the associations of obesity with dyslipidemia and low-grade
systemic inflammation, two strong risk factors for CVD and
diabetes. Although these findings need to be replicated, they
motivate experimental research on the uses of high-dose n-3
fatty-acid supplementation for the attenuation of obesity-
related disease risk.
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